Role of advanced glycation end products and sorbitol dehydrogenase in the pathogenesis of diabetic retinopathy

Bulletin of the National Research Centre

Table 2 Laboratory investigations of diabetics grouped according to DR types

		No.	Mean	SD	Pvalue
FBS	No.	76	223.4	76.4	0.835
	NPDR	85	223.5	79.1
	PDR	105	217.4	84.0
PPBS	No.	76	286.3	81.2	0.437
	NPDR	85	306.2	105.1
	PDR	105	295.8	103.1
HbA1c	No	76	7.65	1.58	0.003*
	NPDR	85	7.81	1.53
	PDR	105	8.00	1.61
AGE	No	76	22.07	18.73	< 0.001*
	NPDR	85	26.49	16.15
	PDR	105	24.13	14.02
Total cholesterol	No	76	230.67	41.03	0.001*
	NPDR	85	231.67	45.16
	PDR	105	239.36	47.46
Triglycerides	No	76	172.47	26.44	0.002*
	NPDR	85	177.81	43.27
	PDR	105	179.98	33.29
HDL	No	76	49.18	11.72	0.001*
	NPDR	85	47.64	11.61
	PDR	105	51.34	10.41
LDL	No	76	152.72	43.19	0.028*
	NPDR	85	148.84	45.86
	PDR	105	151.28	47.10
Creatinine	No.	76	1.0	0.4	0.003*
	NPDR	85	1.0	0.2
	PDR	105	0.9	0.2
Urea	No.	76	42.0	10.2	0.001*
	NPDR	85	40.2	10.8
	PDR	105	36.9	6.6
Lab. test	Comparison A (p value)		Comparison B (p value)		Comparison C (p value)
HbA1c	0.017*		0.002*		0.096
GEP	>0.001*		>0.001*		0.275
Total Cholesterol	0.055		>0.001*		0.151
Triglycerides	0.018		>0.001*		0.347
HDL	0.322		>0.001*		0.014*
LDL	0.23		0.017*		0.607
Creatinine	0.08		0.001*		0.095
Urea	0.21		< 0.001*		0.015*

*According to Table 2, microangiopathy (nephropathy and neuropathy) may not be clinically detected; however, investigations are needed for further diction.
Comparison A between groups without retinopathy and that with NDPR.
Comparison B between groups without retinopathy and with PDR
Comparison C between groups with NDPR and that with PDR
*(Kruskal-Wallis Test, Mann-Whitney U with Bonferroni’s adjustment: lower the significance of P value from 0.05 to 0.017)